AMR Action Fund: 1st investment in weeks, months, page-14

I am trying to find excuses why the PBT2 deal has not been executed within these 10 months ATH has had the patent.

The evident partner, the "fund", has not been ready for a big deal because the Chairperson, Bill Burns, was only appointed 2 months ago and he seems to be still an active, busy person (74 years old). Currently, Burns is a member of the Novo Holdings advisory group, chair of Molecular Partners, Vestergaard Holdings and vice chair of Mesoblast. He has a strong Roche connection ( over 20 years in Roche) and this may also be one issue because Roche is also interested in antibiotic resistance drugs as are Pfizer, Novartis, Teva, and so many other companies.

As you may see, I am thinking of a hybrid deal with private companies, several of them, and then with the Fund, representing also public interests. When I try to figure when Burns really started as the Chairperson, it possibly took some 3-4 weeks. Then he had to orientate himself to his new work and perhaps to read the proposed deal plan and also to give his impact on the issue.

So in the fund, Burns is a Roche person, Skinner a Novartis person, Alter ( external affairs) a Pfizer person. On our side, I think we have some of the scientists from Queensland and perhaps some business experts from Universities

But now everything should be ready if the negotiations are successful to make the deal. I do not find more excuses, the deal to same 700.000 lives must be close. It is everybody's interest.